The study showed no unusual threats, which indicated that it may be properly administered inside of a medical research context. Afterwards, Dr. Charles Grob requested authorization to even more research the substance with cancer clients, but was denied with the FDA two times.02 Many elements add to the copyright experience, such as dose, attitude,